Since Cellectis S.A. (NASDAQ:CLLS) and Equillium Inc. (NASDAQ:EQ) are part of the Biotechnology industry, they are influenced by compare. The influences particularly affect the institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation of both companies.

Earnings & Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectis S.A.	25.47M	29.44	82.53M	-2.11	0.00
Equillium Inc.	N/A	0.00	9.82M	-0.71	0.00

Table 1 highlights Cellectis S.A. and Equillium Inc.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 shows Cellectis S.A. and Equillium Inc.’s return on equity, return on assets and net margins.

	Net Margins	Return on Equity	Return on Assets
Cellectis S.A.	-324.03%	-23%	-18.8%
Equillium Inc.	0.00%	0%	0%

Liquidity

The current Quick Ratio of Cellectis S.A. is 11.2 while its Current Ratio is 11.2. Meanwhile, Equillium Inc. has a Current Ratio of 1.9 while its Quick Ratio is 1.9. Cellectis S.A. is better positioned to pay off its short-term and long-term debts than Equillium Inc.

Analyst Recommendations

Cellectis S.A. and Equillium Inc. Ratings and Recommendations are available on the next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Cellectis S.A.	0	1	0	2.00
Equillium Inc.	0	0	0	0.00

Cellectis S.A.’s upside potential is 41.00% at a $25 consensus target price.

Institutional & Insider Ownership

Roughly 29.4% of Cellectis S.A. shares are owned by institutional investors while 0.99% of Equillium Inc. are owned by institutional investors. Competitively, insiders own roughly 21.3% of Equillium Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Cellectis S.A.	-12.03%	-27.86%	-25.47%	-35.88%	-21.71%	-33.55%
Equillium Inc.	-14.15%	-17.66%	0%	0%	0%	0.57%

For the past year Cellectis S.A. has -33.55% weaker performance while Equillium Inc. has 0.57% stronger performance.

Summary

Equillium Inc. beats on 6 of the 10 factors Cellectis S.A.

Cellectis S.A., a gene-editing company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL) and CLL. The companyÂ’s products also comprise UCART123 for acute myeloid leukemia indications and blastic plasmacytoid dendritic cell neoplasm; UCARTCS1 for multiple myeloma (MM) indications; UCART22 for ALL; and UCART38 for T-cell ALL and MM. In addition, it focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology. The company has strategic alliances with Pfizer Inc. to generate CAR T-cells in the field of oncology; Les Laboratoires Servier SAS to develop and commercialize product candidates; The University of Texas MD Anderson Cancer Center to research and develop novel cellular immunotherapies for patients suffering from various liquid tumors; and Cornell University to accelerate the development of a targeted immunotherapy for patients with acute myeloid leukemia. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Equillium, Inc., a biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is EQ001, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1 clinical trials for the treatment of acute graft-versus-host disease and asthma. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was founded in 2017 and is headquartered in San Diego, California.